lateral humeral epicondylitis, medial humeral epicondylitis, shoulder periarthritis, intractable pain after artificial joint surgery, knee osteoarthritis, hip osteoarthritis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1)Previous conservative therapies applied for at least 3 months and persistent moderate-to-severe hip pain (NRS>=5). 2) Patients with maintain major organ (bone marrow, heart, liver, lung, kidney) function. Hb: more than 10.0g/dL WBC: more than 3,000/mm3, less than 12,000/mm3 Plt: more than 70,000/mm3 Cr: less than 1.5mg/dL 3) 20 years of age or older and less than 80 years of age, gender is unquestioned 4) Patients with possibility of going to hospital and follow up for 6 months. 5) Provided written informed consent to undergo the procedure.
Exclusion criteria
Exclusion criteria: 1)Surgical candidate 2)Patients with major depression 3)Patients with uncontrollable diabetic mellitus 4)Patients without possibility of going to hospital and follow up for 6 months. 5)Patient who was decided not to be appropriate for this trial by physician 6)Patients with a history of hypersensitivity or shock to antibiotics of imipenem . cilastatin, carbapenem, penicillin or cephem 7)Patients who are receiving sodium valproate 8)Patients with a history of severe thrombotic symptoms such as myocardial infarction and cerebral infarction 9)Patients diagnosed as anti-phospholipid antibody syndrome 10)Patients performing antiplatelet drugs or anticoagulation therapy 11)Patients diagnosed as collagen diseases such as rheumatoid arthritis and polymyalgia rheumatic 12)Pregnant patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy 1) Numerical Rating Scale (NRS) in 6 months after the procedure 2) Quality of life (QOL) in 6 months after the procedure | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events | — |
Countries
Japan
Contacts
Wakayama medical university Department of Radiology